María Victoria
Mateos Manteca

Profesora Titular de Universidad

Foto de María Victoria

Foto de Charité

Charité

Berlín, Alemania

Charité-ko ikertzaileekin lankidetzan egindako argitalpenak (4)

2023

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
Leukemia, Vol. 37, Núm. 7, pp. 1521-1529

2022

Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4](S2152265021X00122)
Clinical Lymphoma, Myeloma and Leukemia

2013

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma
Journal of Clinical Oncology

2009

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
Leukemia, Vol. 23, Núm. 10, pp. 1716-1730